A Phase I Study of Repeated Intratumoral Administration of TBI-1401(HF10), a Replication Competent HSV-1 Oncolytic Virus, in Patients With Solid Tumors With Superficial Lesions
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs HF 10 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takara Bio
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
- 27 Oct 2016 Status changed from recruiting to active, no longer recruiting.